High-Dose Ascorbic Acid
High Dose Ascorbic Acid for Plasma Cell Disorders
What will happen during the trial?
This is a phase 1 study for patients with relapsed refractory multiple myeloma. Patients will receive a 15-gram test dose, and a maximum of 3 cycles, each composed of 4 doses of high-dose ascorbic acid (HDAA) and 2 doses of melphalan. This study will enroll 9 patients with relapsed refractory multiple myeloma. The starting dose of ascorbic acid will be 50 grams. Using a 3+3 dose escalation, the dose will potentially increase to 75 grams then 100 grams.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 9 patients (estimated)
- Sponsors
- Holden Comprehensive Cancer Center - University of Iowa
- Tags
- Chemotherapy
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 992
- NCT Identifier
- NCT03602235
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.